Clinical Trials Logo

Relapsed Follicular Lymphoma clinical trials

View clinical trials related to Relapsed Follicular Lymphoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03806179 Completed - Follicular Lymphoma Clinical Trials

Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL

LYMRIT-37-07
Start date: October 4, 2018
Phase: Phase 1
Study type: Interventional

This study is a Phase 1b, open-label, single arm dose escalation study of Betalutin followed by rituximab in patients with previously treated follicular lymphoma. The purpose of this study is to characterise the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of Betalutin in combination with rituximab.

NCT ID: NCT00715208 Completed - Clinical trials for Relapsed Follicular Lymphoma

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Start date: September 2008
Phase: Phase 2
Study type: Interventional

This is a phase 2, two-arm, non-randomized, open-label, multicenter study evaluating the safety and efficacy of 2 VELCADE-containing regimens. Patients will be treated with either a combination of VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone (VELCADE-R-CAP) or a combination of VELCADE, rituximab, cyclophosphamide, and prednisone (VELCADE-R-CP) based on investigator preference. Following completion of the treatment period, patients will receive maintenance therapy with rituximab up to a maximum of 2 years.